Laura Cowen, Author at Labiotech.eu

About

Laura Cowen is a freelance medical journalist. Her background is in medical microbiology, with a particular interest in public health and infectious diseases. Outside of work she enjoys roller skating, trips to the theatre, and exploring the UK and Europe with her family in their new motorhome Bella.

Articles by Laura Cowen

epigenetics oncology car t mnemo therapeutics

News and Trends 22 Jun 2021

Huge Series A in France Strengthens European Epigenetic Oncology

Mnemo Therapeutics has raised €75M in the largest-ever French Series A round, which it will use to develop CAR-T cell immunotherapies for cancer using epigenetic targets. Mnemo Therapeutics’ mammoth financing, led by Casdin Capital, returning investor Sofinnova Partners, and an undisclosed investor, will allow the startup to accelerate the development of its epigenetic targeting and […]

June 22, 2021 - 4 minutesmins - By Laura Cowen

News and Trends 2 Oct 2020

Huge €62M Series B Boost for Mosa Meat’s Cell-Based Burgers

The Netherlands-based food technology company Mosa Meat has raised €62M in a Series B round that will be used to bring its cultured beef products a step closer to the market. The funding round was led by the Luxembourg firm Blue Horizon Ventures in collaboration with the Bell Food Group, M Ventures, and others. Of […]

October 2, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 10 Jul 2020

Life Sciences Fund Launches with €76M to Invest in Nordic Biotech

Stockholm and Copenhagen-based Eir Ventures has announced the closure of its first fund at €76M, which will be used to invest in biotechs and other life science companies, with a focus on the Nordics. The fund is backed by Saminvest, a venture capital company founded by the Swedish Government; Vækstfonden, the Danish state’s investment fund; […]

July 10, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 3 Jul 2020

CRISPR Therapeutics Announces Huge €400M Public Fundraise

The Swiss firm CRISPR Therapeutics has priced a public offering on the Nasdaq Global Market at around €400M, which it will use to develop therapies based on the gene editing tool CRISPR/Cas9 for genetic disorders and cancer. This fundraise is the second-highest global share offering from a European biotech so far this year after the […]

July 3, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 22 Jun 2020

Epidarex Capital Targets UK Biotech with €112M Venture Fund

The transatlantic life science VC Epidarex Capital has closed its third fund at a value of €112.7M, which will be used to build new biotech companies from emerging hubs across the UK. The ‘Epidarex Capital III UK LP’ fund is based on a €55.2M (£50M) commitment from the British Business Bank. The remainder comes from […]

June 22, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 5 Jun 2020

Upsized Nasdaq IPO Yields Calliditas €80M to Commercialize Kidney Drug

Swedish company Calliditas Therapeutics has raised an €80M IPO on the Nasdaq Global Select Market — 20% above its initial target — to fund an ongoing phase III trial of its lead candidate treatment for an inflammatory kidney condition. Calliditas plans to use the net proceeds together with its existing cash resources to fund an […]

June 5, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 28 May 2020

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer. The round was closed on the basis of the company reaching preclinical proof-of-concept for the drug. It brings the total amount raised by Tollys to €6.4M since […]

May 28, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 25 May 2020

Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products

The German companies Evonik and Beiersdorf will work together on a joint research project to investigate how bacteria can be used to turn carbon dioxide (CO₂) and water into raw materials for skincare products. The process will be built on Evonik’s artificial photosynthesis technology – being developed independently of this project in collaboration with Siemens […]

May 25, 2020 - 2 minutesmins - By Laura Cowen

News and Trends 15 May 2020

Affibody Signs €208M Deal To Market Autoimmune Drug in China

Swedish biotech Affibody and Chinese firm Inmagene Biopharmaceuticals will work together to develop and commercialize Affibody’s phase II-stage drug for autoimmune diseases such as psoriasis. Under the agreement, Inmagene will commercialize Affibody’s treatment in the Greater China region and South Korea, as well as develop the drug in the Asia Pacific region excluding Japan. Meanwhile, […]

May 15, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 15 May 2020

Update: ADC Therapeutics’ IPO Hits Above Target with €215M

Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York Stock Exchange far above the initial target of €172M, raising a total of €215.2M ($232.7M). ADC Therapeutics ended up offering more than 12 million shares at a price of €17.57 ($19) per share, which was higher than the €16.65 ($18) […]

May 15, 2020 - 4 minutesmins - By Laura Cowen

genomics machine learning personalized medicine

News and Trends 8 May 2020

€7M Series A To Democratize Genomics with AI-Driven Cloud Software

The UK-based bioinformatics firm Lifebit Biotech has closed a €7M Series A funding round, which will help the startup to accelerate the global market expansion of its AI-driven, cloud-based genomics analysis software. The round was led by the Parisian VC firm Idinvest Partners and also included returning investors Pentech Ventures, Beacon Capital, and Connect Ventures. […]

May 8, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 24 Apr 2020

Big €10M Seed Round Funds New Class of Cancer Drugs in Switzerland

The Swiss biotech FoRx Therapeutics has raised an impressive €10M in seed funding to develop a new generation of drugs that target DNA repair in cancer cells. The drugs will block a DNA repair process called break-induced replication, which was discovered by the company’s scientific founder Thanos Halazonetis. This process is used by cancer cells […]

April 24, 2020 - 3 minutesmins - By Laura Cowen

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us